Quarterly results and guidance from the drugmakers that matter.
Anika Therapeutics reported third-quarter revenue of $30.6 million and raised parts of its 2026 guidance, but the FDA told it in October that its Hyalofast cartilage-repair application cannot be approved.
The company reported third-quarter revenue of $1.3 billion and net income of $162 million, and highlighted US approval of mFLUSIVA alongside mixed pipeline news.
The Nasdaq-listed sidewalk and hospital robot company also cut its non-GAAP operating expense outlook and launched a service offering its technology to other robot makers.
The long-term care pharmacy provider reported $371.1 million in third-quarter revenue, higher net income and adjusted EBITDA growth of 24%, and raised its full-year guidance.
The gene-editing company says it will discontinue clinical development of vispa-cel and CB-011 and is exploring alternatives, including a merger or liquidation, after a difficult financing climate.
The US diagnostics company reported quarterly revenue of $24.0 million, with Diagnostic Testing up 16%, but cited sales force changes, seasonality and delayed development projects.
The aortic disease specialist posted a $7.9M net loss and lower adjusted EBITDA, while preparing a January 2027 US launch of NEXUS.
The shoulder-focused medtech company reported $16.2 million in Q3 net revenue and flagged a new 510(k) clearance, first InSet Go cases, a patent settlement and a distribution partnership.
The single-cell and spatial biology company reported 1% third-quarter revenue growth to $150.7 million and a narrower net loss, while launching a new cloud analysis platform.
The protein-sequencing company reported a $22.3 million quarterly net loss, opened Proteus pre-orders and reaffirmed its cash runway into the fourth quarter of 2028.
The medtech group reported $1.9bn in third-quarter sales as advance orders placed ahead of an ERP cutover reversed, while lifting its adjusted EPS outlook to $7.20-$7.30.
The US genetic testing company reported a narrower non-GAAP loss outlook for 2026 and projected year-end cash and investments of about $630 million.
The RECELL maker reported $26.1 million in Q3 revenue, drew the last $10 million of its Perceptive Advisors facility and removed its going-concern qualification.
The Zio maker reported third-quarter revenue of $221.6 million, completed its VitalConnect acquisition and filed FDA 510(k) applications for paediatric use of Zio Monitor.
The Barostim maker lowered its full-year outlook, pointing to weaker sales force productivity and a drawn-out dispute with a major payer, despite a second Medicare Advantage coverage policy.
The prostate ablation maker also named Richard Fabian as incoming CEO and guided to at least $25.0 million in full-year revenue.
The infusion-therapy company reported a swing to GAAP profit and a wider gross margin, and expects to finish 2026 toward the high end of its guidance.
The US drugmaker reported higher third-quarter sales and profit, but gross margin fell and epinephrine pre-filled syringe releases slowed following an FDA warning letter at its IMS facility.
The gene therapy and exon-skipping company lifted the low end of its net product revenue guidance by $50m and trimmed expense guidance, with two muscle-disease datasets expected this quarter.
Halozyme reported third-quarter revenue of $493.0m, with royalties of $341.0m, and raised its full-year outlook as ENHANZE partner products continued to drive growth.
The US device company reported third-quarter revenue of $1.07m, held its 2026 guidance, and confirmed full enrolment in its Phase III TIGeR-PaC pancreatic cancer trial.
The rare-disease company lifted its 2026 outlook and flagged two 2027 FDA decision dates, for a KHINDIVI label expansion and the newly licensed LIBERVANT NDA.
The company ended the quarter with $272.2m in cash, while partners Novo, Roche and Bristol Myers Squibb progress late- and mid-stage trials.
The US cell therapy company reported about $122M in third-quarter revenue and raised its full-year outlook from $350M-$370M, citing growth in Amtagvi treatment sites.
Gyre Therapeutics affirmed full-year guidance after Q3 results, with an NMPA ruling on hydronidone (F351) for CHB-induced liver fibrosis possible by end-2026 or Q1 2027.
Rigel Pharmaceuticals reported Q3 net income of $13.2 million and raised its full-year revenue guidance after the US launch of VEPPANU, the first FDA-approved PROTAC.
Higher Medicaid and 340B deductions and increased R&D spending cut profit, even as NERLYNX sales grew; Puma also began a Phase II lung cancer trial.
The organ-transplant technology company reported third-quarter revenue of $203.0 million and net income of $17.1 million, alongside FDA IDE approvals and a first European logistics tender win in Italy.
The cell and gene therapy logistics provider reported third-quarter revenue of $50.2 million, a net loss of $10.9 million and adjusted EBITDA of $1.1 million.
MannKind reported $45.0m in commercial product revenue, as the newly shipping Furoscix ReadyFlow and the paediatric Afrezza launch lifted sales, alongside early inhaled-pipeline data and a new licensing deal.